Investor Overview

Investor Overview

Corporate ProfilescPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery — with the goal of transforming infused therapies, advancing patient care and reducing healthcare costs.

Stock Quote

(Common Stock)
Exchange
Volume
Today's Open
Previous Close
Data as of 04/19/24 12:19 AM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart

Current News

March 13, 2024

scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Generated 4Q 2023 net FUROSCIX ® revenue of $6.1 million , at the upper end of the range provided in January and representing sequential growth of 61% from $3.8 million in 3Q 2023 Generated full-year net FUROSCIX ® revenue of $13.6 million , at the upper end of the range provided in January Ended
Read More >

March 6, 2024

scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024

Management to host conference call and webcast at 4:30 p.m. ET BURLINGTON, Mass. , March 06, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient
Read More >

February 28, 2024

scPharmaceuticals to Participate in Two Upcoming Investor Conferences

BURLINGTON, Mass. , Feb. 28, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today
Read More >
Upcoming Events
There are currently no events scheduled.
Presentations